As­traZeneca nabs pri­or­i­ty re­view for Lyn­parza in prostate as PARP in­hibitors ex­pand to more can­cers

Lyn­parza keeps rolling.

Three weeks af­ter the FDA cleared the As­traZeneca drug as a first-line treat­ment of a par­tic­u­lar form of ad­vanced pan­cre­at­ic can­cer, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.